China National Pharmaceutical Group Co., Ltd. Yizhi’s 2025 related-party transaction disclosure: operational dealings as the main focus, with active intercompany fund lending by its subsidiaries.

China Visit Network data. China National Pharmaceutical Group Unanimous Pharmaceutical Co., Ltd. (hereinafter referred to as “Sinopharm Unanimed”) recently disclosed its information on non-operating use of funds and other related party fund transactions for fiscal year 2025. The announcement shows that during the reporting period, the company had no situation in which controlling shareholders, the actual controller, or their affiliated enterprises improperly used listed company funds for non-operating purposes. All related party fund transactions arise from daily purchase-and-sale and labor service activities, and are considered operating transactions; no non-operating fund occupation was found.

In terms of related party transactions, the company has frequent operating accounts receivable transactions with its controlling shareholder, China National Pharmaceutical Holdings Co., Ltd., and many of its fellow subsidiaries. In particular, the ending balance of accounts receivable with China National Pharmaceutical Holdings was RMB 24.05 million, while the total amount accumulated over the full year reached RMB 135.47 million. The accounts receivable transactions with other related parties also involve multiple provincial and municipal companies distributed nationwide within the Sinopharm Holdings group.

Of note, fund lending and borrowing activities between the listed company and its subsidiaries are relatively active. During the reporting period, the company provided large loans to its main controlling subsidiaries, which constitute non-operating transactions. For example, with respect to the loan provided to Sinopharm Holdings Guangzhou Co., Ltd., the beginning balance was RMB 2.42B, the additional loan disbursed during the period was RMB 3.51B, repayments were RMB 4.4B, the ending balance was RMB 1.61B, and interest was accrued at RMB 76.40 million. Similar situations also occurred among more than a dozen subsidiaries such as Sinopharm Holdings Guangxi Co., Ltd. and Sinopharm Holdings Zhanjiang Co., Ltd., where the scale of fund transactions was relatively large and mainly used to support subsidiary operations.

Overall, Sinopharm Unanimed’s related party fund transactions in 2025 were mainly driven by normal operating business, and at the same time, through internal funds allocation, it strongly supported the development of its subsidiaries, reflecting the synergistic effect within the group. The relevant transactions all went through the necessary deliberation and disclosure procedures.

Massive information, precise interpretation—available in the Sina Finance App